-
公开(公告)号：US20220096547A1
公开(公告)日：2022-03-31
申请号：US17420657
申请日：2020-01-03
发明人： Yafeng ZHANG , Shu WU , Zhongyuan TU , Wang ZHANG , Qinghe ZHANG
IPC分类号： A61K35/17 , C07K14/255 , C12N15/63 , C12N5/0783 , C07K14/725 , C07K14/705 , C12N5/16
摘要： Provided are modified immune cells expressing a flagellin polypeptide capable of binding to a toll-like receptor. The modified immune cell further comprises an engineered receptor. Also provided are methods and pharmaceutical compositions for cancer treatment using the modified immune cells.
-
公开(公告)号：US20220073643A1
公开(公告)日：2022-03-10
申请号：US17419203
申请日：2019-12-27
发明人： Liusong Yin , Tielin Zhou , Zhuo Fang , Yong Liu , Qiuchuan Zhuang , Bo Wu , Xiaohu Fan , Qingshan Zhang , Dan Zhao , Jie Mao
摘要： Described herein are binding moieties, such as antibodies, that specifically bind Claudin18.2, and chimeric antigen receptors comprising such binding moieties. Further provided are engineered immune cells (such as T cells) comprising anti-Claudin 18.2 chimeric antigen receptors. Also disclosed are methods of treating Claudin18.2-expressing tumor or cancers using the binding moieties, chimeric antigen receptors and engineered immune cells.
-
公开(公告)号：US20220033481A1
公开(公告)日：2022-02-03
申请号：US16755268
申请日：2017-10-11
发明人： Yafeng ZHANG , Shu WU , Fei SUN , Shuai YANG , Chuan-Chu CHOU
摘要： Novel antibodies, such as single domain antibodies (sdAbs), or antigen-binding fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are also described.
-
公开(公告)号：US20210275590A1
公开(公告)日：2021-09-09
申请号：US17274458
申请日：2019-09-10
发明人： Yafeng ZHANG , Tailan ZHAN , Fei SUN , Jian LIU , Qing ZHANG , Shu WU
IPC分类号： A61K35/17 , C07K16/28 , A61P35/00 , C07K14/725
摘要： The present application provides single-domain antibodies targeting CD33 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune cells (such as T cells) comprising an anti-CD33 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
-
公开(公告)号：US20210070855A1
公开(公告)日：2021-03-11
申请号：US16964828
申请日：2019-01-24
发明人： Tao Zhao , Huihui Zhang , Shuai Yang , Yun Zhang , Chuan-Chu Chou , Shu Wu
摘要： Provided are antibodies including monoclonal, human, primate, rodent, mammalian, chimeric, humanized and CDR-grafted antibodies, and antigen binding fragments and antigen binding derivatives thereof. These antibodies bind to CD47 protein, particularly human CD47, modulate, e.g., inhibit, block, antagonize, neutralize or otherwise interfere with CD47 expression, activity and/or signaling, including inhibiting CD47 and SIRPa interaction; do not cause a significant level of hemagglutination of human red blood cells. These antibodies may not enhance RBC phagocytosis.
-
公开(公告)号：US20210054071A1
公开(公告)日：2021-02-25
申请号：US16958397
申请日：2018-12-28
发明人： Wang ZHANG , Shu WU , Shuai YANG , Qi PAN , Chuan-Chu CHOU
摘要： Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes TIGIT. Also provided are methods of making and using these constructs.
-
公开(公告)号：US20190225668A1
公开(公告)日：2019-07-25
申请号：US16329739
申请日：2017-08-31
发明人： Qiuchuan Zhuang , Xiaohu Fan , Lei Yang , Pingyan Wang
IPC分类号： C07K14/705 , A61K35/17 , A61P35/02 , C12N15/62 , C12N15/86
摘要： The present invention relates to a human CD123-targeting chimeric receptor ligand, comprising an IL-3 molecule-based CD123 binding domain, a transmembrane region, and an intracellular signaling domain. The present invention provides a T cell modified by the human CD123-targeting chimeric receptor ligand and capable of specifically binding with CD123 on tumor cell surfaces, thereby having specific cytotoxicity on tumor cells. The present invention further relates to an application of the human CD123-targeting chimeric receptor ligand and an immune effector cell thereof in preparing an anti-tumor immunotherapy drug.
-
公开(公告)号：US20240279318A1
公开(公告)日：2024-08-22
申请号：US18560661
申请日：2022-05-31
发明人： Mingxin LI , Zhigang LI , Shuai YANG , Ming ZENG , Sujuan Wang , Lan XU , Shu Wu
IPC分类号： C07K16/18 , A61K39/00 , C07K14/705 , C07K14/725 , C07K16/28 , C12N5/0783
CPC分类号： C07K16/18 , A61K39/4611 , A61K39/4631 , A61K39/4644 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/2833 , C12N5/0636 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/622 , C07K2317/92 , C07K2319/02 , C12N2510/00
摘要： This disclosure relates to antibodies, antigen-binding fragments, protein constructs, and chimeric antigen receptors that bind to a complex comprising an AFP peptide and an MHC molecule, and the uses thereof.
-
公开(公告)号：US20240150456A1
公开(公告)日：2024-05-09
申请号：US18282696
申请日：2022-04-02
发明人： Fei XU , Ruidong Hao , Wang Zhang , Shu Wu
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00 , C07K14/705 , C07K14/71 , C12N5/0783
CPC分类号： C07K16/28 , A61K39/4631 , A61K39/4637 , A61K39/464402 , A61P35/00 , C07K14/70521 , C07K14/71 , C12N5/0636 , C07K2319/03 , C12N2510/00
摘要： The present disclosure provides immune effector cells engineered to express a functional exogenous receptor such as a CAR armored with a tumor homing peptide. The immune effector cells according to the present disclosure have enhanced tumor infiltration and anti-tumor efficacy.
-
公开(公告)号：US11958903B2
公开(公告)日：2024-04-16
申请号：US17043054
申请日：2019-03-29
发明人： Wang Zhang , Shuai Yang , Shu Wu , Chuan-Chu Chou
CPC分类号： C07K16/2803 , A61P35/00 , C07K16/2818 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/569 , C07K2317/92
摘要： The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.
-
-
-
-
-
-
-
-
-
搜索结果
63 条记录 (耗时 0.026 秒)
